---
title: Zoledronic acid add-on therapy for standard-risk Ewing sarcoma patients in
  the Ewing 2008R1 trial
date: '2023-10-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37843857/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231016181012&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: In patients with standard-risk localized EWS, there is no
  additional benefit from maintenance treatment with ...'
disable_comments: true
---
CONCLUSION: In patients with standard-risk localized EWS, there is no additional benefit from maintenance treatment with ...